Baker McKenzie has advised a consortium of investors led by SPE Capital, through its Private Equity Fund III (PEF III), on its investment in a European holding company, the parent company of Orchidia Pharmaceutical Industries S.A.E., a leading ophthalmic pharmaceutical manufacturer with operations in Egypt and across the Middle East and Africa.

The investor consortium included the European Bank for Reconstruction and Development (EBRD), Société de Promotion et de Participation pour la Coopération Économique (Proparco), and the Belgian Investment Company for Developing Countries (BIO). The transaction was successfully completed in March 2026.

“We were pleased to support SPE Capital and the investor consortium on this strategically important transaction, drawing on our experience in complex private equity investments in the pharma sector across multiple jurisdictions,” said Hani Nassef, Partner at Baker McKenzie.

Baker McKenzie acted as lead counsel on the transaction, advising and supporting across all aspects of the deal – from the early investment structuring stages and consortium arrangements through to diligence, documentation, signing and completion. The Firm advised across multiple jurisdictions and various stakeholders to support them with a seamless closing of this successful transaction. 

The deal highlights Baker McKenzie’s credentials in advising on private equity investments in regulated sectors, combining deep local insight with seamless execution on complex, multi‑jurisdictional transactions. Delighted to have contributed to another successful milestone for our clients.

The Baker McKenzie team was led by Partner Hani Nassef, with support from Zeinab Shohdy, Ingy Elkady, Hala Mohamed, Hayna Abdelrehim, Chirouette Elmasry, Noureldin El Hayatmy and Hanna Ahmed. Mohamed Elfar, Hania Negm and Mohamed Elbaroudy provided antitrust advice. BLC Roberts & Associates provided Mauritian law advice. Chrysostomides Advocates & Legal Consultants provided Cypriot law advice.